Serdexmethylphenidate/Dexmethylphenidate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Serdexmethylphenidate/Dexmethylphenidate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Serdexmethylphenidate/Dexmethylphenidate can convert its Small molecule drug profile and DAT x NET x α-adrenergic receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Serdexmethylphenidate/Dexmethylphenidate (query alias: Serdexmethylphenidate/Dexmethylphenidate) |
|---|---|
| Modality / target | Small molecule drug; DAT x NET x α-adrenergic receptor; DAT antagonists, NET inhibitors, α-adrenergic receptor agonists |
| Highest global status | Approved |
| Originator | Zevra Therapeutics, Inc. |
| Active developers | Shanghai Ark Biopharmaceutical Co., Ltd., Commave Therapeutics SA, Catalent Greenville, Inc. |
The MCP disease footprint includes Attention Deficit Disorder With Hyperactivity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05668754 | Phase 2 | Completed | 66 | Change From Baseline in Epworth Sleepiness Scale (ESS) Score |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Determine the Safety and Efficacy of Oral SDX in Patients With Idiopathic Hypersomnia (IH)
Phase 2; n=66; evaluation: not stated. Reported fields: Change From Baseline in Epworth Sleepiness Scale (ESS) Score(Mean) = -0.6 score on a scale (95% Confidence Interval, -4.1 to 2.9); -; -
Zevra Therapeutics Presents Full Data Set On The Cardiovascular Safety And Pharmacokinetics Of SDX, The Sole API In KP1077, In Healthy Volunteers At Psych Congress 2023
Phase 1; n=not disclosed; evaluation: Positive. Reported fields: Safety = The study results affirm that SDX is safe and well-tolerated at higher doses and has no greater cardiovascular safety risk than other methylphenidate products currently being used off-label for the treatment of IH while providing higher overall exposure levels of d-MPH.
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
Phase 1; n=15; evaluation: Positive. Reported fields: Cmax = 200 mg SDX being approximately half of the values for Ritalin
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Serdexmethylphenidate/Dexmethylphenidate addresses Attention Deficit Disorder With Hyperactivity. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-10-27 | Corium will market KemPharm's Azstarys for ADHD in the United States. | Approved | Financial terms not disclosed |
| 2019-09-04 | Zevra completed the sale of SDX portfolio to Commave Therapeutics | Phase 2 | US$493.0M stated total |
| 2019-09-03 | Boston Pharmaceuticals will develop and market KemPharm's SDX and d-MPH-based therapeutics for ADHD on a global scale. | Not disclosed | US$10.0M upfront; US$483.0M milestones; US$493.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
